| Literature DB >> 28985434 |
Ellen R A de Bruijn1,2, Margit I Ruissen1,2, Sina Radke3,4.
Abstract
Altered performance monitoring has been demonstrated after administration of different pharmacological compounds and in various clinical populations, such as excessive neurophysiological responses to mistakes in anxiety disorders. Here, a novel social pharmacological approach was applied to investigate whether oxytocin administration (24 IU) enhances performance monitoring for errors that have negative consequences for another individual, so-called social mistakes. Healthy male volunteers (N = 24) participated in a placebo-controlled crossover design. EEG measures were obtained while pairs of participants performed a speeded choice reaction-time task in an individual and social context. Following oxytocin administration, error-related negativity amplitudes were increased for social compared with individual mistakes. This increase was not found in the placebo condition. No effects of oxytocin were present in the individual context. The current study shows that oxytocin enhances performance monitoring specifically for social mistakes. This outcome is in line with a presumed role for oxytocin in salience attribution to social cues and underlines its context-dependency. Combining these processes may thus open up new research avenues and advance our understanding of individual differences in performance monitoring and oxytocin responses from a social neurocognitive, pharmacological and clinical perspective.Entities:
Keywords: error-related negativity (ERN); event-related potential (ERP); oxytocin; performance monitoring; social mistakes
Mesh:
Substances:
Year: 2017 PMID: 28985434 PMCID: PMC5647804 DOI: 10.1093/scan/nsx094
Source DB: PubMed Journal: Soc Cogn Affect Neurosci ISSN: 1749-5016 Impact factor: 3.436
Fig. 1.Experimental setup with two participants seated next to each other behind their own individual computer screens. Both participants performed the task simultaneously while EEG was recorded.
Mean reaction times in milliseconds for all conditions in both the individual and social context. Standard deviations are given in parentheses
| Placebo | Oxytocin | |||||||
|---|---|---|---|---|---|---|---|---|
| Congruent | Incongruent | Congruent | Incongruent | |||||
| Correct | Error | Correct | Error | Correct | Error | Correct | Error | |
| Individual | 334 (39) | 324 (57) | 394 (44) | 286 (42) | 339 (36) | 317 (59) | 399 (33) | 300 (54) |
| Social | 333 (41) | 322 (72) | 391 (48) | 295 (50) | 334 (45) | 318 (75) | 396 (45) | 291 (39) |
Mean error percentages for all conditions in both the individual and social context. Standard deviations are given in parentheses
| Placebo | Oxytocin | |||
|---|---|---|---|---|
| Congruent | Incongruent | Congruent | Incongruent | |
| Individual | 5.4 (3.7) | 25.4 (13.2) | 5.2 (3.9) | 25.5 (12.0) |
| Social | 6.3 (5.4) | 25.7 (12.1) | 7.7 (6.6) | 27.1 (14.3) |
Fig. 2.Mean ERN amplitudes (in µV) of error trials for the placebo and oxytocin condition in the individual and social context for electrodes Fz, FCz and Cz. Error bars represent standard errors of the mean.
Fig. 3.(A) Response-locked grand average waveforms for correct and incorrect responses in the individual and social context in the placebo condition for electrodes Fz, FCz, Cz and Pz. (B) Topographical distributions of the difference waves (incorrect minus correct responses) collapsed over context for the ERN (peak onset at 78 ms, top), the early Pe (peak onset at 229 ms, middle) and for the late Pe (mean amplitude in 300–500 ms time window, bottom).
Fig. 4.(A) Response-locked grand average waveforms for correct and incorrect responses in the individual and social context in the oxytocin condition for electrodes Fz, FCz, Cz and Pz. (B) Topographical distributions of the difference waves (incorrect minus correct responses) collapsed over context for the ERN (peak onset at 85 ms, top), the early Pe (peak onset at 236 ms, middle) and for the late Pe (mean amplitude in 300–500 ms time window, bottom).